SCHEMBL4676736

SCHEMBL4676736

O=C(Cc1ccsc1S(=O)(=O)c1ccccc1)C(=O)c1nc[nH]n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.37
NPSR1 Q6W5P4 1/20 0.35
ALDH1A1 P00352 3/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
MAPK1 P28482 1/20 0.33
PPARG P37231 1/20 0.33
NCOA2 Q15596 1/20 0.33
NCOA1 Q15788 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NAMPT P43490 3/20 0.32
CYP2C9 P11712 1/20 0.32
LMNA P02545 1/20 0.32
GAA P10253 1/20 0.32
MMP2 P08253 2/20 0.31
MMP8 P22894 2/20 0.31
MMP12 P39900 2/20 0.31
MMP13 P45452 2/20 0.31
MMP14 P50281 2/20 0.31
MMP16 P51512 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671745 0.90 MMP1 (0.33) ALDH1A1KMT2AMEN1CYP2C9LMNA
SCHEMBL4673073 0.90 ALDH1A1 (0.35) NPSR1ALDH1A1LMNAGAARAB9A
SCHEMBL4677580 0.82 CES1 (0.36) POLBNPSR1ALDH1A1KMT2AMEN1
SCHEMBL4674637 0.82 NPSR1 (0.43) POLBNPSR1ALDH1A1KMT2ANAMPT
SCHEMBL4674765 0.80 MMP2 (0.36) NPSR1ALDH1A1KMT2ANAMPTMMP2
SCHEMBL4670967 0.80 MMP2 (0.37) ALDH1A1KMT2ANAMPTMMP2MMP8
SCHEMBL4675261 0.79 TP53 (0.50) ALDH1A1KMT2AMAPK1HSD17B10RAB9A
SCHEMBL4673018 0.79 NAMPT (0.34) ALDH1A1KMT2AMEN1NAMPTCYP2C9
SCHEMBL4674716 0.78 HDAC1 (0.33) ALDH1A1NAMPTMMP2MMP8MMP12
SCHEMBL4676442 0.78 MMP2 (0.36) ALDH1A1KMT2ANAMPTMMP2MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 POLB 58/4885NPSR1 937/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.